Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An announcement from Mega Genomics Limited ( (HK:6667) ) is now available.
Mega Genomics Limited has scheduled a board meeting for 31 March 2026 to review and approve the group’s audited final results for the financial year ended 31 December 2025. The board will also consider recommending a final dividend for shareholders, if any, and may address other corporate matters at the meeting.
The timing of the meeting signals that the company is moving toward the next phase of its financial reporting cycle and could soon provide investors with clarity on its full-year performance. Any decision on a final dividend will be closely watched by shareholders as an indicator of the company’s profitability, cash position, and confidence in its near-term outlook.
More about Mega Genomics Limited
Mega Genomics Limited is a Cayman Islands–incorporated company listed on the Hong Kong Stock Exchange under stock code 6667. The group operates in the genomics sector, though the announcement provides no additional detail on its specific products, services, or market focus. The board comprises executive, non-executive, and independent non-executive directors based in Hong Kong and mainland China.
Average Trading Volume: 9,272
Technical Sentiment Signal: Hold
Current Market Cap: HK$1.53B
Find detailed analytics on 6667 stock on TipRanks’ Stock Analysis page.